NuCana (NASDAQ:NCNA) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of NuCana (NASDAQ:NCNA) from a hold rating to a buy rating in a research note published on Tuesday, BidAskClub reports.

A number of other brokerages have also issued reports on NCNA. Piper Jaffray Companies reissued an overweight rating and issued a $25.00 price objective (down previously from $35.00) on shares of NuCana in a report on Friday, August 23rd. Zacks Investment Research raised shares of NuCana from a hold rating to a strong-buy rating and set a $8.75 target price for the company in a research note on Saturday, August 24th. Citigroup set a $25.00 target price on shares of NuCana and gave the stock a buy rating in a research note on Wednesday, August 21st. William Blair reaffirmed a buy rating on shares of NuCana in a research note on Thursday, September 5th. Finally, ValuEngine raised shares of NuCana from a hold rating to a buy rating in a research note on Thursday, August 1st. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $19.69.

Shares of NCNA traded up $0.09 during mid-day trading on Tuesday, reaching $9.00. The stock had a trading volume of 204 shares, compared to its average volume of 200,900. NuCana has a 52-week low of $4.01 and a 52-week high of $25.82. The business’s fifty day moving average is $8.77 and its 200 day moving average is $12.18. The firm has a market cap of $310.01 million, a price-to-earnings ratio of -15.79 and a beta of 3.19.

A number of hedge funds have recently made changes to their positions in NCNA. Asymmetry Capital Management L.P. increased its stake in NuCana by 5.4% in the first quarter. Asymmetry Capital Management L.P. now owns 45,393 shares of the company’s stock valued at $772,000 after purchasing an additional 2,346 shares during the last quarter. Marshall Wace North America L.P. grew its position in shares of NuCana by 558.8% during the first quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock worth $1,034,000 after acquiring an additional 51,607 shares during the last quarter. Rothschild Investment Corp IL grew its position in shares of NuCana by 126.1% during the second quarter. Rothschild Investment Corp IL now owns 28,075 shares of the company’s stock worth $291,000 after acquiring an additional 15,660 shares during the last quarter. Aperio Group LLC purchased a new position in shares of NuCana during the second quarter worth approximately $39,000. Finally, BlackRock Inc. grew its position in shares of NuCana by 134,310.2% during the second quarter. BlackRock Inc. now owns 608,878 shares of the company’s stock worth $6,320,000 after acquiring an additional 608,425 shares during the last quarter. 36.11% of the stock is owned by institutional investors.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Further Reading: Sell-Side Analysts

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.